Total

Quartiles

1^st

2^nd

3^rd

4^th

5^th

Study

Patients

Populat-

Patients on

Patients on

Patients on CLP & ASP

Patients on Clopidogrel, Aspirin, PPI

on CLP

ion

PPI’s

Statins

with PPI

and Statins

& ASP

(n 116)

(n 31)

(n 19)

(n 16)

(n 28)

(n 22)

CLP &

CLP &

CLP &

CLP &

CLP & ASP

CLP & ASP

ASP

ASP

ASP

ASP

RAB

PAN

SIM

ROS

with

with

with

with

with RAB

with PAN

(n 12)

(n 7)

(n 10)

(n 6)

RAB &

RAB &

PAN &

PAN &

(n 17)

(n 11)

SIM

ROS

SIM

ROS

(n 9)

(n 6)

(n 5)

(n 2)

Age, yrs

55 ± 19

48 ± 16

50 ± 15

45 ± 3

55 ± 10

60 ± 9

50 ± 14

60 ± 12

45 ± 7

65 ± 9

54 ± 8

48 ± 10

Male, n

88 (75)

27 (90)

8 (66)

4 (57)

7 (70)

5 (83)

14 (82)

9 (82)

9 (100)

2 (33)

5 (100)

1 (50)

(%)

Body

Mass

-

25.9 ± 3.8

25.1 ± 3

28 ± 2.

24.6 ± 2.

23.1 ± 3

25.3 ± 3.2

27 ± 2.1

24 ± 1

22 ± 3.3

21 ± 4.3

27 ± 2.2

Index

.4

9

3

.3

(kg/m²)

Risk factors for CAD, n (%)

Cigarette

39 (34)

17 (55)

3 (25)

3 (43)

4 (40)

2 (33)

6 (35)

5 (45)

2 (22)

4 (67)

3 (100)

0 (0)

smoking

Hypertesion

35 (30)

6 (19)

1 (8)

1 (14)

5 (50)

4 (67)

5 (29)

6 (55)

2 (22)

3 (50)

1 (33)

1

Diabetes

13 (11)

0 (0)

2 (17)

0 (0)

2 (20)

1 (17)

2 (12)

3 (27)

0 (0)

2 (33)

1 (33)

0

mellitus

Dyslipide

33 (28)

5 (16)

2 (17)

1 (14)

4 (40)

3 (50)

5 (29)

3 (27)

1 (11)

5 (83)

3 (100)

2 (100)

mia

Family

history of

21 (18)

8 (26)

3 (25)

2 (29)

3 (30)

5 (83)

9 (53)

5 (45)

3 (33)

4 (67)

1 (33)

1 (50)

MI

Initial clinical characteristics, n (%)

Previous

52 (45)

5 (16)

4 (33)

1 (14)

5 (50)

3 (50)

4 (24)

4 (36)

0 (0)

1 (17)

0 (0)

1 (50)

MI

Anterior

28 (24)

6 (19)

3 (25)

2 (29)

6 (60)

1 (17)

6 (35)

2 (18)

1 (11)

3 (50)

0 (0)

0 (0)

infarction

In-hospital medical therapy, n (%)

Statins

61 (53)

0 (0)

0 (0)

0 (0)

10

6

0 (0)

0 (0)

9 (100)

6 (100)

5 (100)

2 (100)

(100)

(100)

Anti-

17 (15)

0 (0)

2 (17)

0 (0)

2 (20)

1 (17)

2 (12)

3 (27)

0

2 (33)

1 (33)

0

Diabetic

β-

14 (12)

7 (23)

1 (8)

1 (14)

1 (10)

0 (0)

2 (12)

0 (0)

1 (11)

1 (17)

0 (0)

0 (0)

Blockers